Anti-sense oligonucleotide labeled with technetium-99m using hydrazinonictinamide derivative and N-hydroxysuccinimidyl S-acetylmercaptoacetyltriglycline: A comparison of radiochemical behaviors and biological properties

Abstract

AIM: To explore and compare the radiochemical behavior and biological property of anti-sense oligonucleotide (ASON) labeled with technetium-99m using N-hydroxysuccinimidyl S-acetylmercaptoacetyltriglycline (NHS-MAG₃) and hydrazinonictinamide derivative (HYNIC).

METHODS: After HYNIC and NHS-MAG₃ were synthesized, ASON was labeled with technetium-99m using HYNIC and NHS-MAG₃ as a bifunctional chelator. The in vivo and in vitro stability, binding rates of labeled compounds to serum albumen, biodistribution of ^99mTc-MAG₃-ASON and ^99mTc-HYNIC-ASON in BALB/C mouse and its HT29 tumor cellular uptake were compared.

RESULTS: The labeling efficiency and stability of ^99mTc-MAG₃-ASON were significantly higher than those of ^99mTc-HYNIC-ASON (P = 0.02, and P = 0.03, respectively). ^99mTc-MAG₃-ASON had a significantly lower rate of binding to serum albumen than ^99mTc-HYNIC-ASON (P < 0.05). In contrast to ^99mTc-HYNIC-ASON, the biodistribution of ^99mTc-MAG₃-ASON was significantly lower in blood, heart, liver and stomach (P < 0.05), slightly lower in intestines and spleen (P > 0.05) and significantly higher in lung and kidney (P < 0.05). The HT29 tumor cellular uptake rate of ^99mTc-MAG₃-ASON was significantly higher than that of ^99mTc-HYNIC-ASON (P < 0.05).

CONCLUSION: ^99mTc-MAG₃-ASON shows superior radiochemical behaviors and biological properties than ^99mTc-HYNIC-ASON. ^99mTc-MAG₃-ASON is a potential radiopharmaceutical agent for in vivo application.

Key Words: Anti-sense oligonucleotide; Radiolabeling; Technetium-99m; N-hydroxysuccinimidyl S-acetylmercaptoacetyltriglycline; Hydrazinonictionamide derivative

INTRODUCTION

Different drugs can be used in anti-sense therapy, among which synthetic anti-sense oligonucleotide (ASON) is used to bind to deoxyribonucleic acid (DNA) translation or transcription in a sequence-specific manner and interfere with the expression of oncogene. However, it is still difficult for ASON to target tumor cells and transport across cell membrane. Besides, because of multi-gene expressions in tumor cells, inhibition of any single target gene is not sufficient to inhibit tumor growth. Radio-labeled ASON targeting specific oncogenes can overcome these problems by direct inhibition of anti-sense and radiation damage. The curative effect of radionuclide anti-sense therapy is closely related to the labeling efficacy of ASON and the characteristics of labeled compounds. In contrast to ¹⁸⁸Re, ¹⁸⁶Re, ⁹⁰Y[1–3], hydrazinonictinamide derivative (HYNIC) and N-hydroxysuccinimidyl S-acetylmercaptoacetyltriglycline (NHS-MAG₃), as a bifunctional chelator, have been known to help label ASON[4–6] with ^99mTc. However, few reports are available on the comparison of both chelators. This study was to compare the radiochemical behaviors and biological properties of ASON labeled with technetium-99m using NHS-MAG₃ and HYNIC.

MATERIALS AND METHODS

Materials

BALB/c nude mice at the age of 6-8 wk, weighing 17-22 g, were obtained from West China Experimental Animal Center. Human colon carcinoma HT29 cell line was obtained from the Laboratory of West China Hospital. HT29 cells were incubated in RPMI 1640 supplemented with 10% fetal calf serum, 100 U/mL penicillin, 100 &mgr;g/mL streptomycin. Fifteen-mer phosphorothioate ASON (5’-NH₂-FACGTTGAGGGGCAT-3’, F is adenosine sulfurised), which is complementary to the translation start site of c-myc mrRNA, was purchased from GiBcoBRL (USA). ^99mTcO₄^- (37 TBq/L) was obtained from Chengdu Gaotong Isotope Corporation (Chengdu, China). Sephadex G25 was from Pharmacia Fine Chemicals A.B (Uppsala, Sweden). C₁₈ Sep-Pak reversed-phase column was a product from Waters Company (Milford, USA). CRC-15R dose calibrator was from Capintec Company (Ramsey, New Jersey, USA). FH463A automatic scaler was supplied by Beijing Nuclear Instrument Company (Beijing, China). Unity Inova-400 nuclear magnetic resonator was from Varian Company (USA). UV-2100 spectrophotometer was from Beckman Company (Cotati, California, USA). Frozen desiccator was from Marathon Electric Company (New York, USA). CO₂ incubator was from Sanyo Company (Japan). Centrifuge was from Beckman Company (Cotati, California, USA).

Synthesis of HYNIC and NHS-MAG₃

HYNIC was synthesized as previously described[7] (Figure 1). The end product was purified by recrystalli-zation in isopropyl alcohol and the yield was 75%. The synthesis process of NHS-MAG₃ has been described elsewhere[6] (Figure 2). The melting temperature of the end product was 140°C-155°C, the yield was 80%. The content was 2.38 ppm (S, 3H, SCOCH₃), 2.80 ppm (S, 4H, succinimidyl), 3.68-3.80 ppm (M, 8H, COCH₂) and 8.20-8.38 ppm (M, 3H, NHCO), respectively, by nuclear magnetic resonance spectroscopy.

Figure 1 Synthesis of HYNIC.

Figure 2 Synthesis of NHS-MAG₃. S-acetylthioglycolic acid N-hydroxysuccinimide ester (SATA) was initially synthesized from acetic acid. S-acetyl MAG₃ was obtained by the reaction of SATA and triglycine. NHS-MAG₃ was produced with the coupling of S-acetyl MAG₃ and N-hydroxybudityrylimine.

^99mTc labeling ASON via HYNIC

ASON (2 mg/mL) buffer was dissolved in 2 mol/L NaCl, 0.5 mol/L NaHCO₃ and 2 mmol/L ethylenediamine tetraacetic acid (EDTA), and HYNIC (10 mg/mL) was dissolved in dimethylformamide (DMF). In 45°C water bath, 31 &mgr;L HYNIC and 2 mmol/L EDTA were gradually dropped into a 25 &mgr;L ASON solution at the molar ratio of 25:1. The reaction system was filtered through a Sep-Pak C18 reversed-phase column (10 mm × 5 mm) in 60% methanol to remove HYNIC not binding to ASON. HYNIC-ASON was collected with a UV-2100 spectrophotometer and frosted to dry powder for storage. HYNIC-ASON dry powder was labeled on d 15, 30 or 60, respectively. Ten &mgr;g HYNIC-ASON powder was dissolved in a 0.5 mL tricine solution (70 mg/mL). SnCl₂·2H₂O solution (1 mg/mL) was dissolved in 0.1 mol/L HCl at room temperature. HYNIC-ASON solution, 25 &mgr;L SnCl₂·2H₂O solution and 0.2 mL ^99mTcO₄^- containing a radioactivity of 370, 740 or 1480 MBq were mixed uniformly. After stored for 30 min at room temperature, the mixture was eluted and purified through a Sep-Pak C18 reversed-phase column (10 mm × 5 mm) in 60% methanol, and ^99mTc-HYNIC-ASON solution was collected. Chromatographic assay was performed in both solution systems before and after purification to detect the labeling efficacy and radio-chemical purity of ^99mTc-HYNIC-ASON, where Xihua I filter paper as a sustentaculum was developed with 85% methanol as a developer.

^99mTc labeling ASON via NHS-MAG₃

Twenty-five microliter ASON (2 mg/mL, dissolved in 0.25 mol/L NaHCO₃ and 1 mol/L EDTA, pH = 8.5) was mixed with 42 &mgr;L NHS-MAG₃ (10 mg/mL, dissolved in dimethylsulphoxide) at the molar ratio of 1:25. The mixture reacted at room temperature in the dark for 15 min. Any free NHS-MAG₃ was removed through Sep-Pak C18 reversed-phase column (10 mm × 5 mm) in 60% methanol. The bound MAG₃-ASON was collected with a spectrophotometer and frosted to dry powder for storage. The target-bound complex, dry powder on d 15, 30 or 60 at room temperature, was labeled. Fifty &mgr;L MAG₃-ASON (1 mg/mL) in re-distilled water was mixed with 10 &mgr;L NaHCO₃ (0.5 mol/L)-sodium tartrate (50 mg/mL) buffer (pH = 9.2). Ten &mgr;L SnCl₂·2H₂O fresh solution (1 mg/mL, dissolved in 0.1 mol/L HCl) was dropped into MAG₃-ASON at room temperature and mixed uniformly. At last, 0.2 mL ^99mTcO₄^- (containing a radioactivity of 370, 740 or 1480 MBq) was added into the above solutions, respectively. After 15 min, ^99mTc-ASON-MAG₃ was purified on Sephadex G25 column (250 mm × 5 mm) in an ammonium acetate solution (0.25 mol/L, pH = 5.2) and collected. Chromatographic assay was performed in both specimens before and after purification to evaluate the labeling efficiency and radiochemical purity. A system was demanded to develop Xihua I filter paper in 85% methanol.

Stability of labeled compounds

The stability of labeled compounds was assessed for 1, 2 and 4 h, respectively, at room temperature, by measuring the radiochemical purity on Xihua I filter paper that was developed in 85% methanol.

Test for plasma protein binding in rabbits

Three hundred and seventy mL MBq ^99mTc-HYNIC-ASON or ^99mTc-MAG₃-ASON was mixed with 2 mL anti-coagulated rabbit fresh plasma for 6 cuvettes. After incubated at 37 °C for 2 h, the mixture was mixed with 5 mL trichloroacetic acid (250 g/L) and centrifuged for 5 min at 1200 ×g. The precipitate was washed twice with 2 mL trichloroacetic acid (250 g/L) and the supernatant was collected. The radioactivity of precipitate and supernatant was measured, respectively. The binding rate of ^99mTc-HYNIC-ASON or ^99mTc-MAG₃-ASON to rabbit plasma protein was calculated by the following formula: Binding rate (%) = radioactivity of precipitate/radioactivity of precipitate and supernatant.

Tissue distribution of labeled compounds in BALB/c mice

^99mTc-HYNIC-ASON or ^99mTc-MAG₃-ASON (0.2 mL, 148 KBq) was separately injected into the tail veins of 20 BALB/c nude mice (age: 6-8 wk, body weight: 17-22 g) which were randomly divided into four groups (5 in each group). Mice in each group were sacrificed at 0.5, 1, 2 and 4 h, respectively, after injection of ^99mTc-HYNIC-ASON or ^99mTc-MAG₃-ASON. Blood, heart, lungs, liver, kidneys, spleen, stomach, intestine and muscles were removed and weighed. The tissue uptake rate of labeled compounds was calculated according to the following equation: tissue uptake rate (%ID/g) = radioactivity of per gram of wet tissue weight/radioactivity of wet tissue injected into the body. The results were expressed as percentage of radioactivity within per gram of wet tissue.

Cellular uptake of labeled compounds

Human colon carcinoma HT29 cells were incubated with RPMI 1640 medium containing 10% fetal calf serum, 100 U/mL penicillin and 100 &mgr;g/mL streptomycin. Tumor cells were cultured in 80 wells of 96-well plates (1.5 × 10⁶ cells/well). It took about 24 h for cells to adhere to wells. The culture medium was pipetted and 2 mL serum-free RPMI 1640 medium containing 74 KBq ^99mTc-HYNIC-ASON or ^99mTc-MAG₃-ASON was added to each of the 80 wells. The cells were incubated in a humidified incubator containing 50 mL/L CO₂ at 37°C for 10, 20, 40, 60 and 120 min, respectively. Each well was rinsed 3 times with RPMI 1640 medium. At last, all the human colon carcinoma HT29 cells and supernatant in each well were collected and the radioactivity was calculated. The following formula was used to calculate the percentage of radioactivity within the cells of each well: cellular uptake rate (%) = radioactivity absorbed in each well/radioactivity added to each well.

Statistical analysis

The data were expressed as mean ± SD and input into a computer for statistical analysis with SPSS 11 software. Differences among the groups were compared with paired t-test. P < 0.05 was considered statistically significant.

RESULTS

Labeling efficiency and radiochemical purity of labeled compounds

Analysis of labeling efficiency and radiochemical purity of the labeled compounds showed that the flow rate of ^99mTc-HYNIC-ASON and ^99mTc-MAG₃-ASON, ^99mTcO₄^-, and deoxidized technetium, was 0.9-1.0, 0.6-0.7, and 0-0.1, respectively. The labeling efficiency and radiochemical purity of labeled compounds are listed in Table 1. The labeling efficiency of ^99mTc via NHS-MAG₃ was higher than that of ^99mTc via HYNIC (for interval between binding and labeling: t = 6.715, P = 0.021; for radioactivity of ^99mTcO₄^-: t = 11.736, P = 0.007). The radioactivity of ^99mTcO₄^- hardly influenced the labeling efficiency. The radiochemical purity of labeled compounds was higher than 95% and there was no statistical difference between the two methods (for interval between binding and labeling: t = -0.444, P = 0.701; for radioactivity of ^99mTcO₄^-: t = 2.656, P = 0.117). Either interval between binding and labeling of HYNIC-ASON or that of MAG₃-ASON had almost no effect on the labeling efficiency and radiochemical purity of labeled compounds.

Table 1 Labeling efficacy and radiochemical purity of labeled compounds (mean ± SD).

	Interval between binding and labeling (d)			Radioactivity of 99mTcO4- (MBq)
	15	30	60	370	740	1480
Labeling efficiency (%)
Via HYNIC	57.36 ± 3.69	62.13 ± 4.25	62.87 ± 3.04	58.74 ± 5.32	62.86 ± 4.27	63.28 ± 3.38
Via NHS-MAG3	67.35 ± 4.03	68.35 ± 3.56	69.85 ± 4.63	68.67 ± 4.82	70.31 ± 5.09	71.56 ± 5.37
Radiochemical purity (%)
99mTc-HYNIC-ASON	95.75 ± 5.21	96.32 ± 4.92	95.86 ± 5.28	96.56 ± 4.45	96.87 ± 3.65	97.16 ± 4.34
99mTc-MAG3-ASON	96.43 ± 4.69	95.67 ± 5.17	96.39 ± 4.78	96.35 ± 6.12	95.86 ± 4.67	96.54 ± 5.65

ASON: Anti-sense oligonucleotide; HYNIC: Hydrazino nicotinamide derivative; NHS-MAG₃: N-hydroxysuccinimidyl S-acetylmercaptoacetyltriglycline.

Radiochemical purity of labeled compounds

To assess the radiochemical purity, the labeled compounds were incubated at room temperature or at 37°C after diluted with an equal volume of fresh human serum (Table 2). The radiochemical purity of ^99mTc-MAG₃-ASON was much higher than that of ^99mTc-HYNIC-ASON (at room temperature: t = 5.616, P = 0.030; at 37°C: t = 5.616, P = 0.032), while the radiochemical purity of ^99mTc-MAG₃-ASON was less affected by incubation time than that of ^99mTc-HYNIC-ASON.

Table 2 Radiochemical stability of labeled compounds (%, mean ± SD).

	Incubation time at room temperature (h)			Incubation time at 37°C (h)
	1	2	4	1	2	4
99mTc-HYNIC-ASON	93.43 ± 5.32	89.17 ± 4.62	87.16 ± 5.36	92.75 ± 4.46	89.52 ± 3.67	86.86 ± 5.49
99mTc-MAG3-ASON	97.26 ± 6.02	96.68 ± 5.54	96.39 ± 4.68	95.86 ± 5.69	95.47 ± 4.07	94.79 ± 5.34

Binding rate of rabbit plasma protein

The binding rate of rabbit serum protein for ^99mTc-MAG₃-ASON or ^99mTc-HYNIC-ASON was 11.17% ± 1.31% and 71.06% ± 3.56%, respectively. The differences between them were statistically significant, and the former was lower than the latter (t = 27.346, P < 0.0001).

Biodistribution of ^99mTc-MAG₃-ASON and ^99mTc-HYNIC-ASON in BALB/c mice

The biodistributions of ^99mTc-MAG₃-ASON and ^99mTc-HYNIC-ASON in BALB/c mice are listed in Table 3. The distributions of ^99mTc-MAG₃-ASON were significantly lower in blood, heart, liver and stomach than those of ^99mTc-HYNIC-ASON (P < 0.05). The distributions of ^99mTc-MAG₃-ASON were significantly higher in lungs and kidneys than those of ^99mTc-HYNIC-ASON (P < 0.05). There was no statistical difference in the distributions of ^99mTc-MAG₃-ASON and ^99mTc-HYNIC-ASON in spleen, intestines and muscle.

Table 3 Biodistribution of labeled compounds in BALB/c mice (% ID/g) (mean ± SD).

Tissue	0.5 h		1 h		2 h		4 h		Paired	t-test
	M	H	M	H	M	H	M	H
Blood	1.12 ± 0.76	6.21 ± 1.03	2.38 ± 0.63	6.56 ± 1.11	1.14 ± 0.42	3.58 ± 1.21	1.10 ± 0.09	2.83 ± 0.54	t = 4.347	P = 0.022
Heart	0.62 ± 0.31	2.13 ± 0.45	0.58 ± 0.07	1.64 ± 0.34	0.32 ± 0.05	1.16 ± 0.12	0.18 ± 0.08	0.81 ± 0.13	t = 5.362	P = 0.013
Lungs	3.11 ± 0.82	2.68 ± 0.65	3.87 ± 1.36	3.23 ± 1.04	3.04 ± 0.79	2.78 ± 1.03	2.08 ± 0.62	1.76 ± 0.36	t = -4.934	P = 0.016
Liver	7.52 ± 2.45	11.46 ± 2.31	13.19 ± 1.47	15.24 ± 2.53	9.21 ± 1.03	12.89 ± 1.68	9.48 ± 2.56	10.46 ± 1.97	t = 3.806	P = 0.032
Kidneys	11.42 ± 3.34	4.17 ± 1.05	17.13 ± 2.86	5.03 ± 0.94	24.58 ± 3.57	2.78 ± 0.68	21.95 ± 4.02	2.28 ± 0.95	t = -4.511	P = 0.020
Spleen	2.71 ± 1.62	4.87 ± 2.36	5.65 ± 0.93	6.08 ± 1.93	5.35 ± 0.26	4.08 ± 1.54	4.84 ± 1.33	5.21 ± 2.04	t = 0.603	P = 0.589
Stomach	1.08 ± 0.86	7.46 ± 2.13	2.58 ± 0.95	11.48 ± 3.01	1.73 ± 0.21	7.49 ± 1.86	1.41 ± 0.34	7.85 ± 3.02	t = 9.901	P = 0.002
Intestines	0.53 ± 0.31	1.26 ± 0.31	0.86 ± 0.14	2.68 ± 0.95	1.23 ± 0.19	6.44 ± 2.13	1.96 ± 0.53	7.84 ± 2.34	t = 2.706	P = 0.073
Muscle	1.35 ± 0.16	0.54 ± 0.21	0.87 ± 0.63	0.94 ± 0.81	0.75 ± 0.08	0.42 ± 0.06	0.64 ± 0.15	0.19 ± 0.05	t = -2.095	P = 0.127

M: ^99mTc-MAG₃-ASON; H: ^99mTc-HYNIC-ASON. Statistical analysis of the same tissue distribution of radioactivity was made after the injection of ^99mTc-HYNIC-ASON and ^99mTc-MAG₃-ASON.

Cellular uptake of labeled compounds

Cellular uptake of labeled compounds in human colon carcinoma HT29 cells is listed in Table 4. The cellular uptake of ^99mTc-MAG₃-ASON was significantly higher than that of ^99mTc-HYNIC-ASON (t = 3.770, P = 0.020), which was 6.5, 10.1, 8.4, 9.5 and 9.1-folds higher than those of ^99mTc-HYNIC-ASON at 10, 20, 40, 60 and 120 min after incubation.

Table 4 Human colon carcinoma HT29 cellular uptake of ^99mTc-HYNIC-ASON and ^99mTc-MAG₃-ASON (mean ± SD).

	10 min	20 min	40 min	60 min	120 min
99mTc-HYNIC-ASON (%)	0.43 ± 0.08	0.56 ± 0.21	0.93 ± 0.54	1.42 ± 0.64	1.67 ± 0.86
99mTc-MAG3-ASON (%)	2.78 ± 0.81	5.64 ± 0.51	7.82 ± 2.53	13.63 ± 2.71	15.25 ± 3.13

DISCUSSION

In our studies, because expensive acetylsulfoacetic acid was not available, S-acetylthioglycolic acid N-hydroxysuccinimide ester (SATA) was synthesized as previously described[5]. The synergenic coligand of tricine (N-tris-hydroxy-methyl-methylglycine) was applied to the synthesis of HYNIC, to achieve the high radioactivity of labeled compounds. During the synthesis of labeled compounds, isopropylol was used to crystallize the compounds instead of chromatographic column purification. Their synthesis was simple, efficient, economical, with a high yield (75%-80%) and little environmental pollution. Nuclear magnetic resonance of labeled compounds was performed as previously described[5–7]. Both Sep-Pak C18 reversed-phase column and Sephadex G25 column could be used to purify the radiolabeled ASON. Both labeling methods can achieve a high radiochemical purity of over 95%.

Stability can be obtained by methylation, amination or sulfonation of the phosphorus atoms in ASON, making it not recognized and degradated by nucleic acid enzyme[8]. In the present study, we modified the ASON by replacing the hydroxyl group in the phosphoric acid branch of ASON with a sulphur atom and attaching an amid to the 5′ terminal of ASON. Labeled compounds were observed for four hours to detect the stability of ASON labeled with ^99mTc via HYNIC or NHS-MAG₃. Only 1-2 covalent bonds were formed between a molecule of HYNIC-ASON and a technetium atom. However, it was reported that 4-5 covalent bonds can form between MAG₃-ASON and technetium[910], which may be the reason for a greater stability of ^99mTc-MAG₃-ASON than that of ^99mTc-HYNIC-ASON. During labeling, since the mercapto group of ASON-MAG₃ is protected by acetyl group, excessive SnCl₂ is needed to hydrolyze the protection group of ASON-MAG₃[11], which may be the reason for a greater labeling efficiency of ^99mTc via NHS-MAG₃ than via HYNIC.

The binding rate of ^99mTc-MAG₃-ASON to rabbit serum protein was significantly lower than that of ^99mTc-HYNIC-ASON in our study, suggesting that the distributions of ^99mTc-MAG₃-ASON are significantly lower in blood, heart and liver of BALB/c mice. The distributions of ^99mTc-MAG₃-ASON were much lower in stomach than those of ^99mTc-HYNIC-ASON, suggesting that ^99mTc-MAG₃-ASON has a greater in vivo ability than ^99mTc-HYNIC-ASON. The distributions of ^99mTc-MAG₃-ASON were much higher in kidneys than those of ^99mTc-HYNIC-ASON, which may be related to the metabolism of MAG₃-ASON in kidneys.

Cellular targeting uptake of ASON can be improved by receptor-mediated mechanisms[12–14]. The conjugation of vasoactive intestinal peptide (VIP)-ASON is very helpful for ¹²⁵I-ASON to selectively bind to HT29 tumor cells by VIP receptors. For such tumor cells that highly express VIP receptors, tumor cellular uptake of VIP-¹²⁵I-ASON is significantly higher than that of ¹²⁵I-ASON un-conjugated to VIP[12]. The c-myc ASON complex entered human melanoma cells (M14) by folacin receptors on tumor cell surface, brings about a greater cellular uptake than that of free-ASON, and inhibits tumor growth by lowing c-myc cancer protein expression[13]. As we know, the c-myc oncogene and transferrin receptors are highly expressed in HL-60 and LoVo Dx cells, the addition of transferrin-polylysine-c-myb ASON complex would cause more tumor cell deaths than free c-myb ASON[14]. However, receptor mediation was not used in our study. Why HT29 cellular uptake of ^99mTc-MAG₃-ASON is higher than that of ^99mTc-HYNIC-ASON is unclear, which is possibly related to the greater stability of ^99mTc-MAG₃-ASON, and needs further study.

COMMENTS

Background

Anti-sense oligonucleotide (ASON) is used to bind to deoxyribonucleic acid (DNA) translation or transcription and interfere with the expression of oncogene. However, ASON is not sufficient to inhibit tumor growth. In order to enhance anti-tumor effect of ASON, we labeled ASON with technetium-99m via N-hydroxysuccinimidyl S-acetylmercaptoacetyltriglycline (NHS-MAG₃) and hydrazinonictinamide derivative (HYNIC).

Research frontiers

Many proteins such as monoclonal antibody, polypeptide, ligand, can be labeled with radionuclides, such as ¹²⁵I, ¹³¹I, ³²P, ³⁵S, ^99mTc, ¹⁸⁸Re, ¹⁸⁶Re, ⁹⁰Y. We are trying to label oncolytic virus with radionuclide, in order to achieve a synergistic anticancer effect.

Innovations and breakthroughs

In this study, we compared the radiochemical behaviors and biological properties of anti-sense oligonucleotide (ASON) labeled with technetium-99m via N-hydroxysuccinimidyl S-acetylmercaptoacetyltriglycline (NHS-MAG₃) and hydrazinonictinamide derivative (HYNIC) and found that ^99mTc-MAG₃-ASON showed superior radiochemical behaviors and biological properties than ^99mTc-HYNIC-ASON.

Applications

^99mTc-MAG₃-ASON showed superior radiochemical behaviors and biological properties than ^99mTc-HYNIC-ASON, suggesting that it can be used as a potential radiopharmaceutic agent for in vivo application.

Peer review

In this study, the authors analyzed and compared the radiochemical behaviors and biological properties of anti-sense oligonucleotide (ASON) labeled with technetium-99m via NHS-MAG₃ and HYNIC. The rationale of the study is clearly expressed and the experiments appear to be carefully conducted.